TypeOneBIS Community License (TCL) Version 1.3

Description: The TypeOneBIS Community License (TCL) Version 1. 3 is a self-executing, tier-based public license governing the use, modification, and commercial deployment of the TypeOneBIS Biogenic Replicator platform — a programmable, cell-free molecular assembler capable of synthesising sequence-defined polymers including DNA, RNA, proteins, polysaccharides, and chimeric molecules from a digital sequence file, without fermentation, purification, or cold-chain distribution. The TCL establishes four tiers of access: Tier 1 grants free, unrestricted use to academic institutions, non-profit research organisations, government laboratories, and individual researchers conducting non-commercial research; Tier 2 grants free commercial use to micro-enterprises whose annual net revenue from replicator-manufactured products does not exceed US\100, 000; Tier 3 imposes a minimum annual royalty of US\1, 000 plus 3% of net revenue above US\100, 000 on larger commercial operators; and Tier 4 requires Enterprise Entities — organisations with annual global revenue exceeding US\100, 000, 000 or publicly listed companies — to negotiate separate Field-Exclusive Commercial License Agreements with TypeOneBIS on fair, reasonable, and non-discriminatory (FRAND) terms. The TCL incorporates a mandatory, non-waivable Sovereign Access Carve-Out requiring all licensees to make replicator-manufactured products available at cost in WHO-designated low-income countries, crisis zones, humanitarian field operations, government emergency stockpiling programmes, and off-world installations. Off-world installations are deemed in perpetual Sovereign Access compliance by virtue of their operational context. A Most Favored Community Hub Terms provision ensures that favorable access terms granted to any licensee automatically extend to all Community Hub operators. The TCL establishes the Replicator Foundation — an independent non-profit organisation to be funded by TypeOneBIS through a perpetual contribution beginning at 10% of gross replicator-derived royalty revenue and scaling to 30% or more as the Foundation demonstrates operational capacity. The Foundation's authority is delegated in phases corresponding to demonstrated performance. TypeOneBIS permanently retains Tier 4 enterprise licensing authority and a permanent board seat with an irrevocable Governance Challenge Right, enforceable through a specialist Mission Alignment Tribunal. The Foundation does not collect revenue on TypeOneBIS's behalf at any phase. The TCL incorporates an asymmetric dispute resolution architecture under which TypeOneBIS holds unilateral forum selection rights for any claim brought against it, with a Negotiated Forum Alternative available to licensees who agree to bear all of TypeOneBIS's legal costs regardless of outcome. TypeOneBIS's own enforcement rights are unlimited and may be exercised in any court of competent jurisdiction globally. The license adopts a remedial philosophy in which only a competent court or arbitral tribunal may order termination of a licensee's rights, and only after exhaustion of a good-faith remedial cascade. Additional provisions address compiler modifications and independently developed implementations, sublicensing conditions, confidentiality obligations for Enterprise Entities, force majeure, pipeline protection for Tier 3 licensees, records retention, version control with 90-day notice of material changes, and a plain-language summary positioned at the head of the document for non-legal readers. Acceptance is established by use without requirement of signature or other formal act. The TCL is published alongside the TypeOneBIS Biogenic Replicator white paper (Zenodo DOI: 10. 5281/zenodo. 20586311) and the pending global patent application with priority date 27 May 2026. Keywords: biogenic replicator, molecular assembly, programmable synthesis, cell-free synthesis, microfluidics, hierarchical merge architecture, addressable carriers, photocleavable caps, nLock, pLock, sequence-defined polymers, DNA synthesis, protein synthesis, polysaccharide synthesis, chimeric molecules, open license, community license, sovereign access, global health equity, humanitarian access, Replicator Foundation, TypeOneBIS Community License, TCL, field-exclusive commercial license, FRAND, enterprise licensing, platform-as-a-service, WHO prequalification, disaster resilience, food security, deep space biological autonomy, off-world installations, prior art, freedom to operate License: Creative Commons Attribution-NonCommercial 4. 0 International (CC BY-NC 4. 0) Resource Type: Legal Document / License Publication Date: 2026-06-02 Version: 1. 3 Language: English Related Identifiers: Is supplement to: 10. 5281/zenodo. 20586311 (TypeOneBIS Biogenic Replicator Platform White Paper) Publisher: Robert Ledgister (TypeOneBIS) Contact: replicator@typeonebis. com Rights: This license document is published under CC BY-NC 4. 0. The TypeOneBIS Biogenic Replicator platform is protected by pending and granted patents with priority date 27 May 2026 and PCT applications claiming that priority. Use of the platform is subject to the terms of this Community License.